Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Borštnar Simona) .

1 - 10 / 89
First pagePrevious page123456789Next pageLast page
1.
Rituximab affects the prognosis of patients with nonHodgkin's lymphomas
Barbara Jezeršek Novaković, Marjeta Vovk, Simona Borštnar, Radka Tomšič, 2004, original scientific article

Abstract: Backround. Rituximab - the most widely used monoclonal antibody in the B cell lymphoid malignancies has been applied successfully in the treatment of relapsed and refractory indolent CD20 positive B cell lymphomas and more recently, also in the treatment of aggressive lymphomas in combination with standard chemotherapy. Albeit the chemo-immunotherapy has a wide range of potential applications, there are still several issues that have to be resolved: (1) the optimal scheduling of antibody-chemotherapy combinations, (2) the most active of these combinations, as well as (3) the predictors of response to rituximab. Patients and methods. To facilitate addressing the first two questions, we performed an analysis in 25 patients with different histological types of CD20 positive nonHodgkin's lymphomas (10 aggressive and 15 indolent). Seventeen patients were treated with chemo-immunotherapy for a relapse, and just in 8 patients rituximab was added to first line chemotherapy. Most of the responders received the CHOP regimen, but also otherregimens (FC, BVCPP) were effective in combination with rituximab. Results. The overall response rate was 76%, with 68% complete remissions. The median response duration has not been reached yet. The response was markedly better in the group of previously untreated patients, where the overall response rate reached 100%, with 7 patients in complete and 1 patient in partial remission. Most of the treatment failures occurred in heavily pretreated patients with aggressive lymphomas. No serious adverse effects wereobserved. Conclusion The chemo-immunotherapy improves the treatment outcomes in patients with untreated and relapsed CD20 positive nonHodgkin's lymphomas in comparison to chemotherapy alone. The combined treatment is the most effective when used as soon as possible (preferably as the first line treatment). (Abstract truncated at 2000 characters).
Published in DiRROS: 07.02.2024; Views: 138; Downloads: 32
.pdf Full text (4,61 MB)

2.
Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer
Simona Borštnar, Tanja Čufer, Ivan Vrhovec, Zvonimir Rudolf, 1999, original scientific article

Abstract: Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2.
Published in DiRROS: 22.01.2024; Views: 135; Downloads: 36
.pdf Full text (548,70 KB)

3.
The urokinase-type plasminogen activator, its inhibitors and its receptor - the new prognostic factors in solid cancers
Simona Borštnar, Tanja Čufer, Zvonimir Rudolf, 1997, review article

Abstract: The urokinase-type plasminogen activator (uPA), its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR) play nan important role in the degradation of the intercellular tissue, the process which affects the ability of cancer cells to invade to surrounding tissue and to metastasize. The results of clinical studies performed in the past few years point out a significant influence of uPA, PAI-1, PAI-2 and uPAR on the course of the disease and survival of patients with solid tumours, particularly breast cancer. Hopefullythe categorization of patients according to the content of the serineproteases and its inhibitors in tumour tissues could provide a basis formore rational treatment planning and thus improving patients' survival.
Published in DiRROS: 18.01.2024; Views: 110; Downloads: 36
.pdf Full text (485,80 KB)

4.
5.
Differential diagnosis between bone metastases and osteomalacia
Branko Zakotnik, Simona Borštnar, Tadeja Movrin, Boris Jančar, Andreja Zidar, 1996, original scientific article

Abstract: In oncology the diagnosis of skeletal metastases is a frequent one, in infact so frequent that other diagnoses such as metabolic bone diseases affecting patients with cancer may be overlooked. In our report two cases of osteomalacia referred to an oncologist are presented; in both of them the diagnosis of diffuse bone metastases of unknown origin was suspected. The differential diagnosis is discussed and the importance of bone marrow biopsy using Yamshidi needle for diagnosis of metabolic bone disease is emphasized.
Published in DiRROS: 16.01.2024; Views: 117; Downloads: 31
.pdf Full text (318,84 KB)

6.
Pristopi k zdravljenju raka dojk
Simona Borštnar, 2023, published professional conference contribution

Keywords: rak dojk, zdravljenje, sistemsko zdravljenje
Published in DiRROS: 08.01.2024; Views: 129; Downloads: 37
.pdf Full text (354,25 KB)

7.
Šola raka dojk : [strokovno srečanje]
2023, not set

Keywords: epidemiologija, presejanje, genetsko svetovanje, rehabilitacija, rekonstrukcija, zborniki
Published in DiRROS: 11.12.2023; Views: 198; Downloads: 58
.pdf Full text (14,08 MB)

8.
9.
Novosti na področju imunoterapije dojk
Simona Borštnar, 2023, published scientific conference contribution

Abstract: Z odkritjem in razpoznavanjem vloge zaviralcev imunskih kontrolnih točk (ZIKT) pri številnih solidnih rakih in potrditve imunogenosti trojno negativnega raka dojk (TNRD), je imunoterapija postala privlačna strategija zdravljenja tudi pri tej bolezni. Čeprav so se ZIKT kot monoterapija izkazali za večinoma neučinkovite, pa je več kasnejših raziskav pokazalo, da kombinacija kemoterapije in ZIKT izboljša rezultate zdravljenja v primerjavi s kemoterapijo samo tako pri razsejanem in tudi zgodnjem TNRD. Atezolizumab v kombinaciji z nab-paklitakselom in pembrolizumab v kombinaciji s taksani ali platino in gemcitabinom so standardno zdravljenje pri bolnikih s prvim razsojem PD-L1 pozitivnega raka dojk. Neoadjuvantna terapija s pembrolizumabom in kemoterapijo pa je standardni pristop pri zgodnjem TNBC. Pri ostalih podtipih raka dojk zaenkrat še ni na voljo dokazov o učinkovitosti ZIKT.
Keywords: imunoterapija, onkologija, onkološko zdravljenje
Published in DiRROS: 16.02.2023; Views: 304; Downloads: 153
.pdf Full text (16,12 MB)
This document has many files! More...

10.
Značilnosti zdravljenja, učinkovitosti in varnosti eribulina pri bolnicah z razsejanim rakom dojk : raziskava iz realnega sveta
Luka Dobovišek, Simona Borštnar, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 14.02.2023; Views: 304; Downloads: 76
.pdf Full text (46,32 KB)

Search done in 0.27 sec.
Back to top